Table 3 Methylation percentages between the studied groups in the six CpG sites
From: PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer
CpG site | Control group | Malignant group | P | |||
CpG 1 | Â | Â | 0.009* | |||
 Median (IQR) | 3 (0-5) | 11 (3-19) | ||||
CpG 2 | Â | Â | 0.025* | |||
 Median (IQR) | 2 (0-6) | 9 (0-18) | ||||
CpG 3 | Â | Â | 0.025* | |||
 Median (IQR) | 6 (0-21) | 24 (9-47) | ||||
CpG 4 | Â | Â | 0.036* | |||
 Median (IQR) | 5 (0-11) | 9 (4-33) | ||||
CpG 5 | Â | Â | 0.036* | |||
 Median (IQR) | 3 (0-9) | 10 (2-37) | ||||
CpG 6 | Â | Â | 0.082 | |||
 Median (IQR) | 4 (0-12) | 13 (0-29) | ||||
Average CpG | Â | Â | 0.018* | |||
 Median (IQR) | 5 (2.83-10.5) | 11.83 (5.67-35.5) | ||||
CpG site | a) Control without mass | b) Control with mass | c) Malignant group | P1 | P2 | P3 |
CpG 1 | Â | Â | Â | 0.016* | 0.255 | 0.004* |
 Median (IQR) | 3.50 (3.0 – 7.0) | 0.0 (0.0 – 4.0) | 11 (3-19) | |||
CpG 2 |  |  |  | 0.078 | > 0.05 | > 0.05 |
 Median (IQR) | 2.50 (0.0 – 6.0) | 0.0 (0.0 – 6.0) | 9 (0-18) | |||
CpG 3 |  |  |  | 0.055 | > 0.05 | > 0.05 |
 Median (IQR) | 5.50 (0.0 – 12.0) | 11.0 (1.0 – 23.0) | 24 (9-47) | |||
CpG 4 | Â | Â | Â | 0.044* | 0.013* | 0.253 |
 Median (IQR) | 1.50 (0.0 – 11.0) | 6.0 (3.0 – 12.50) | 9 (4-33) | |||
CpG 5 |  |  |  | 0.074 | > 0.05 | > 0.05 |
 Median (IQR) | 3.0 (0.0 – 6.0) | 4.0 (1.0 – 13.5) | 10 (2-37) | |||
CpG 6 |  |  |  | 0.075 | > 0.05 | > 0.05 |
 Median (IQR) | 2.0 (0.0 – 5.0) | 6.0 (1.50 – 16.5) | 13 (0-29) | |||
Average CpG | Â | Â | Â | 0.036* | 0.014* | 0.123 |
 Median (IQR) | 3.17 (2.67 – 6.67) | 5.83 (3.17 – 12.67) | 11.83 (5.67-35.5) | |||